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TITLE 
THE EFFECT OF GEL FORMULATED SILDENAFIL ON AXIALLY BASED 
RABBIT SKIN FLAP SURVIVAL – AN EXPERIMENTAL STUDY 
ABSTRACT 
Introduction 
Skin flap survival is one of the most important outcomes in reconstructive surgery. Various 
pharmacological agents have been studied previously with mixed results. Sildenafil has been 
shown to improved flap survival experimentally with variable dosing regimens and method of 
applications.  
The objective of this study is to determine the effect of our formulation of sildenafil gel that 
will be applied topically on the epidermal surface of rabbit skin flap to augment flap survival. 
Material and methods 
Six New Zealand rabbits (weight range 2.5-3.2kgs, 3 Female and 3 Male) were divided into 2 
groups; control group (n=3) and treatment group (n=3). A standard protocol of perioperative 
care, anaesthesia, antibiotics, dressings and feeding regimen were followed. A standard 
oversized rabbit skin flap (14X5cm) based on superficial inferior epigastric vessels was 
designed and raised. Subsequently, the flaps were rendered to two hours of ischemic time with 
vascular clamp at the pedicle, released and flaps were sutured back. An aliquot of 1ml gel 
consisted of sildenafil (3mg) was applied immediately after surgery to the distal half of the flap 
in treatment group while on 1 mg gel without sildenafil was applied to control group. 
Measurements with Laser Doppler Flowmetry (LDF) at both distal and central flap were 
performed in all rabbit pre-surgery, post-operative day 1, 3, 5, 7 and 10. Area of necrosis of the 
skin flaps were measured using 2-plane planimetry and photographed. 
vii 
Result and discussion 
Mean flap survival in the treatment group was 99.59%, nearing total flap survival as compared 
to the control group of 85.96% with significant improvement in flap survival of 13.35% as 
compared to control group. Early and late blood flow improvements were observed at both 
central and distal part of flap with significant increased seen at distal flap on postoperative day 
1 (133.50 PU treatment group versus 30.63 PU control group, p<0.05) and on central flap at 
postoperative day 10 (152.17 PU treatment group versus 84.93 PU control group, p<0.05). We 
postulated that sildenafil improved skin flap perfusion via early vasodilatory effects (within 72 
hours) and late angiogenic effects (after 72 hours) of skin flap surgery.  
Conclusion 
The present study has demonstrated that with single application of gel formulated sildenafil 
(3mg), there was a significant improvement in rabbit’s skin flap survival via early and late 
increases of blood flow at the microcirculation.  
Key words: ‘topical sildenafil’, ‘skin flap survival’, ‘microcirculation blood flow’ 
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TAJUK 
KEBERKESANAN APLIKASI GEL FORMULASI TOPIKAL ‘SILDENAFIL’ UNTUK 
MENINGKATKAN KETAHANAN TRANSPLANTASI KULIT ARNAB SECARA 
EKSPERIMEN   
ABSTRAK 
Kejayaan prosedur transplantasi kulit merupakan ukuran penting di dalam bidang pembedahan 
plastik dan rekonstruktif. Terdapat pelbagai jenis ubat yang telah dikaji untuk meningkatkan 
tahap kejayaan prosedur tersebut tetapi menghasilkan keputusan yang tidak konsisten. 
Sildenafil telah terbukti secara eksperimen dapat meningkatkan kadar kejayaan prosedur 
transplantasi kulit menggunakan pelbagai dos ubat dan cara aplikasi yang berbeza-beza.   
Objektif utama kajian ini adalah untuk menentukan keberkesaan formulasi sildenafil 
yang akan digunakan secara topikal ke atas transplantasi kulit arnab untuk meningkatkan 
ketahanan kulit transplantasi. 
Metodologi 
Enam ekor arnab New Zealand (berat di antara 2.5 kg dan 3.2 kg, 3 ekor jantan dan 3 ekor 
betina) dibahagikan secara rawak kepada dua kumpulan; kumpulan kawalan (n=3) dan 
kumpulan intervensi (n=3). Satu protokol standard meliputi pemakanan, bius, ubatan 
antibiotik, prosedur pembedahan dan penjagaan luka selepas pembedahan telah dipraktikan ke 
atas semua haiwan eksperimen. Satu rekabentuk flap kulit standard berdimensi 14 sm dan 5 sm 
yang bergantung kepada salur darah superficial inferior epigastric vessels telah dihasilkan pada 
semua haiwan eksperimen menggunakan kaedah pembedahan. Salur darah tersebut dikepilkan 
dengan clamp untuk menahan aliran darah masuk ke dalam flap kulit selama dua jam. Selepas 
itu, clamp dilepaskan untuk membenarkan aliran darah masuk ke flap kulit, diikuti dengan 
jahitan balik flap kulit kepada tempat asal. Satu milliliter (ml) formulasi sildenafil 
ix 
(mengandungi dos 3 miligram (mg) sildenafil) telah diaplikasikan secara topikal pada 
sebahagian hujung flap kulit untuk kumpulan intervensi manakala gel dengan kuantiti sama (1 
ml) tanpa sildenafil telah diaplikasikan pada kumpulan kawalan. Kertas grid standard (1 sm 
dan 1 sm) digunakan untuk membuat ukuran dimensi flap kulit dan Laser Doppler Flowmetry  
(LDF) telah digunakan untuk mengukur pergerakan aliran darah flap kulit pada hujung dan 
tengah-tengah flap. Semua ukuran dibuat sebelum pembedahan, sejurus selepas pembedahan, 
pada hari pertama, ketiga, kelima dan kesepuluh.  
Keputusan dan diskusi 
Purata kehidupan flap kulit di dalam kumpulan intervensi adalah 99.59 peratus berbanding 
85.96 peratus di dalam kumpulan kawalan. Ini menunjukan terdapat peningkatan sebanyak 
13.35 peratus dari segi kehidupan flap kulit. Di samping itu, terdapat penigkatan ketara aliran 
darah pada tengah-tengah dan hujung flap kulit pada hari pertama selepas pembedahan di 
dalam kumpulan intervensi berbanding kumpulan kawalan (133.50 PU kumpulan intervensi  
berbanding 30.63 PU kumpulan kawalan, p<0.05). Peningkatan aliran darah juga telah 
meningkat secara ketara pada hari kesepuluh di tengah-tengah flap kulit (152.17 PU kumpulan 
intervensi berbanding 84.93 PU kumpulan kawalan, p<0.05). Ini telah membuktikan bahawa 
formulasi sildenafil yang diaplikasikan secara topikal dapat meningkatakan tahap kejayaan flap 
kulit melalui dwi kesan iaitu; pengembangan salur darah pada peringkat awal dan kemungkinan 
penghasilan salur darah baru (angiogenesis) pada peringkat lewat (selepas 72 jam). 
Kesimpulan 
Kajian ini telah membuktikan bahawa aplikasi sekali formulasi 3 mg sildenafil secara topikal 
pada flap kulit arnab dalam eksperimen ini dapat meningkatkan kehidupan flap kulit melalui 
dwi kesan pada peringkat awal dan akhir pembedahan transplantasi.  
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1. INTRODUCTION 
1.1 Literature review 
 
1.1.1 Background  
 
Flap survival remains the most important outcome measure in any flap reconstructive 
surgery. Flap failure can result in total failure or partial failure secondary to inadequate flap 
perfusion. Failure of flap surgery will results in devastating complication to the patient with 
higher cost, prolong hospitalization and possibly more surgery with additional donor site 
morbidity. Recent refinements in microsurgery has ensure high success rate in free tissue 
transfer approaching 95 percent(1-3). However, most common clinical problem in flap surgery 
is partial necrosis rather than total flap failure. Satisfactory perfusion of bulky perforator flaps, 
random or pedicled flaps and functional muscle flaps remains a challenging problem for 
reconstructive surgeons(4).  
Flap is defined as a unit of tissue comprises of its own intrinsic blood supply for 
survival(5). Flap can be transferred from donor to recipient site with its attached vascular 
supply (pedicled flap) or using microsurgical technique to anastomose its inherent blood supply 
to recipient bed (free flap). The intrinsic blood supply of a flap is the most critical determinant 
of successful transfer. Distal flap ischemia usually results from the inability to maintain critical 
capillary pressure to perfuse the most distal part of the flap where total flap failure is usually 
caused by global insufficiency of blood supply secondary to mechanical obstruction to the 
pedicle, or no reflow phenomenon(4). Partial or distal flap necrosis is unavoidable is certain 
clinical conditions despite refinements in microsurgery. It is attributed to the development of 
low flow state at the level of microcirculation caused by improper flap design, vasospasm, 
ischemic reperfusion injury, and systemic factors affecting microcirculation or physical 
compression of the flap.  
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Understanding the anatomic, hemodynamic and metabolic changes during flap transfer 
in a free or pedicled flap will determine the flap viability. Angiosome concept was first 
described by Taylor and Palmer in 1987 and has since become well accepted in the field of 
plastic and reconstructive surgery(5). It allows the conceptualization of the vascular supply to 
all tissues of the human body. An angiosome is a composite block of tissue supplied by a main 
source vessel. This concept indicates that the three-dimensional block of tissue is supplied by 
a major source of artery and acoompanying veins. The adjacent angiosomes are linked either 
by reduced calibre choke anastomotic vessels or vessels without reduction in calibre; the true 
(simple) anastomoses on the arterial side. The choke vessels can potentially dilate to the calibre 
of a true anastomosis after surgical delay or pharmacological manipulation. Improper flap 
design exceeding the intrinsic blood supply for the flap often leads to partial flap necrosis. 
Hence, this angiosome concept is applicable in any flap reconstructive surgery.   
 
An acutely raised flap is both viable and ischemic. In normal hemodynamics, blood 
flow in the flap tip decreases 20% below normal levels within first 6 to 12 hours(1, 6). During 
the first 12- 18 hours, leukocyte-mediated endothelial damage, release of sympathethic 
vasoconstrictors and combination of decreased perfusion pressure flow dramatically decreases 
in the distal flap regions(7). Nutritive supply at the distal or marginal skin flap edge is 
compromise and this will lead to partial flap necrosis especially in the random part of the flap. 
When tip regions are exposed to severe ischemia for 6- 12 hours with no reflow-phenomenan 
sets in, tissue necrosis results in cellular changes in microcirculation level. By understanding 
the fundamental pathophysiology of flap microcirculation, various study has been conducted 
to further explained and proposed various pathogenic pathway leading to flap failure. As a 
result, various methods have been proposed to augment the flap survival based on these 
pathway. 
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Various surgical and non-surgical methods have been proposed to augment the survival 
of flaps; surgical delayed remains the most well understood technique to improve flap survival. 
Early studies proposed that delayed mechanism is caused by alteration in sympathetic tone with 
loss of temporarily hyperadrenagic state in delayed flaps, dilatation of choke vessels and 
reorientation of vessels axially and early changes in tissue metabolism with increase tolerance 
to ischemia in delayed flaps(8, 9). The focus has shifted towards the late effect of vascular 
delayed especially with the recent advances in vascular stem cell biology. Various cytokines 
and angiogenic factors notably the VEGF (Vascular Endothelial Growth Factor) and bFGF 
(basic fibroblast growth factor) were demonstrated to increase following delay and 
subsequently improve neovascularization of flaps(10). However, this procedure has its 
disadvantage of only being available before the main surgery and requires a two-staged 
procedure with significant time delayed. 
Many pharmacological agents have been introduced and studied experimentally to 
improve survival of flap, however clinical outcome is still controversial. These agents include 
sympatholytics, vasodilators, calcium channel blockers, anticoagulants, volume expander 
agents, prostaglandin inhibitors and antioxidants. It can be classify based on three pathogenetic 
entity namely on thrombosis (anti aggregants and anticoagulants), ischemia-reperfusion injury 
or the no-reflow phenomenan (drugs that modulate flap tolerance to ischemia) and vasospasms. 
Antithrombotic and antiplatelet agents were associated with risk of bleeding and outcome were 
often unpredictable(11, 12). On the other hand, various pharmacological agents targeting at 
ischemic reperfusion has shown promising results experimentally, however comparison among 
studies were difficult due to heterogenous experimental model with variable timing and dosing 
of agents used. Hence, these results were difficult to be translated into clinical practice. In 
addition, many of these agents studied may cause important systemic side effects and deemed 
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unsuitable for clinical use. At present, there are only several agents used clinically to prevent 
or relieve vasospasm intraoperatively during microsurgical free tissue transfers(13). Topical 
nitroglycerin has been used experimentally and in small clinical case series to improve flap 
survival, however with variable outcome(14-16). Hence, there is still a continue search for 
more effective pharmacological intervention with exact timing, method of delivery and dosing 
regimen without harmful side effects from the drug itself.  
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1.1.2 The medication– Sildenafil 
Sildenafil citrate is an amphoteric drug with a ph-dependent solubility. Oral tablets is marketed 
as Viagra with doses of 25, 50 and 100 mg taken not more than once daily(17). Oral 
administration encounters various obstacles. The drug is vulnerable to considerable intestinal 
and hepatic first pass metabolism of approximately 71% of oral dose. The drug is metabolized 
in the liver by the enzyme cytochrome P3A4 with an oral bioavailability of 40%. Furthermore, 
numerous side effects such as blood pressure reduction, headaches, flushing and nasal 
congestion are concomitant with oral administration. With oral administration, the effect is 
relatively delayed with onset 30-45 minutes and short duration of action (half-life 4 hours). 
Repeated doses are required to sustain drug plasma levels(18). 
The majority of sildenafil do not appear to penetrate the skin at a sufficiently high rate 
to show therapeutic effectiveness(19). Hence, the feasibility of transdermal route is limited to 
powerful actives presenting features such as appropriate low molecular weight and high 
lipophilicity. Additional challenges faced in formulating sildenafil given the fact that sildenafil 
citrate is amphoteric in nature and ph-dependent characteristics of the compound. The drug 
possesses poor solubility in both aqueous and oil phases. In different ph environment, the drug 
will have different levels of ionization following influence of the partition coefficient, as well 
as its permeation ability via the skin.  
Therefore, modification of the permeation parameters of sildenafil citrate has been 
reported as a major task in development of an optimal drug for topical delivery formula. 
Yonessi and Saeedi investigated the effect of topical gel containing sildenafil (1% in different 
cosolvents) compared to oral sildenafil for erectile dysfunction(19). They reported significantly 
shorter onset of action and lower side effects for transdermal delivery. However, only 12.5% 
patients had complete erection with transdermal sildenafil as compared to 70% patients 
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receiving oral therapy. Other options to increase percutaneous absorption include addiditonal 
of several enchancers and to improve sildenafil delivery characteristics using nanocarriers.   
In our laboratory, we have managed to formulate polymeric gel of Sildenafil with a 
mixture of 1g of sildenafil in 100 ml distilled water, carbomer (Carbopol 941) to give structural 
network and additional of sodium lauryl sulfate (SLS) as penetration enhancer(20). The 
psyhchochemical properties were determined and its stability with enhancer was ascertained. 
Ex vivo permeation study were performed with rabbit skin using a modified jacketed vertical 
Franz diffusion cell to ascertain the amount of sildenafil permeation of the formulated gel(21).  
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1.1.3 Animal model - Rabbit 
Rabbit has served as an excellent model to study cutaneous vascular changes in a skin flap 
surgery. The rabbit abdominal flaps based on inferior epigastric vessels has been investigated 
in several experimental models, including epigastric fasciocutaneous free flap model for study 
of effect of venous hypertension(22), prefabricated abdominal skin flap(23), ischemia-
reperfusion flap model(24), epigastric skin flap model for the study of delay phenomenon(9), 
SIEA fascia flap(25) and venous flap model based on thoracoepigastric vein(26).  
The rabbit is chosen as the flap model in our study due to several advantages. It has 
been noted to be an excellent model for studies due to its ease of handling and husbandary, 
abundant blood supply, insignificant growth rate and more importantly large and consistent 
anatomy of the abdominal skin flap inferior epigastric vessels(8, 9). These advantages of larger 
and consistent vessels anatomy allow ease of surgical dissection and inferior epigastric vessels 
for clamping. The larger abdominal flaps as compare to rodents also provide better evaluation 
of flap perfusion and survival at different zones of the flap with various techniques including 
laser Doppler flowmetry and more accurate measurement of area of necrosis with paper 
template technique. In addition, rabbit has been used in various research for drug delivery 
system via transdermal route such as topical medication in view of the close homology to 
human skin especially the thickness of strateum corneum(27, 28). It also provide an excellent 
model to detect any significant skin reaction towards topical products, additives or enhancers 
used(29).  
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Figure 1. Blood supply of rabbit’s abdominal and dorsal regions. Adopted from Taylor GI, 
Minabe T. The angiosomes of the mammals and other vertebrates. Plast Reconstr Surg. 
1992;89:181(30) 
Deep circumflex iliac 
artery (DCIA) 
Thoracodorsal 
arteries (TA) 
Superficial inferior 
epigastric artery 
(SIEA) 
Lateral thoracic 
artery (LTA) 
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Figure 2. Modified abdominal flap design based on unilateral inferior epigastric vessels; 
translated from original design by Taylor and Minabe.  
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1.2 Rational of the study 
The NO/cGMP pathway has gained interest of many recent studies due to the beneficial 
effect of nitric oxide on microcirculation. Recent studies has shown that sustained cGMP 
enhancing effect of NO have potential effect on wound healing, neuroprotection and 
neurogenesis, vascular relaxation on cardiac muscle and pulmonary arterial systems and 
angiogenesis through gene modulation(31-36). It acts directly on vascular endothelium by 
activating the second messenger signalling pathway for prostacyclin and nitric oxide, namely 
cyclic adenosine monophosphate (cAMP) or cyclic guanosine monophosphate (cGMP) to 
produce vascular smooth muscle relaxation through inhibition of myosin light chain kinase. 
Phosphodiesterase are a family of enzymes that inactivate cAMP and cGMP. There are eleven 
different types of phosphodiesterase (PDE) which are distributed throughout the body with 
only three selectively hydrolyse cGMP relative to cAMP(31). Both PDE-3 and PDE-5 have a 
high affinity for vascular smooth muscle and platelets, hence has been the most studied 
phosphodiesterase in skin flap surgery. By inhibiting phosphodiesterase, dephosphorylation of 
cGMP is prevented, thus allowing NO/GC/cGMP-mediated vasodilation to be sustained for a 
longer period. 
One of the most widely used oral medication in the class of phosphodiesterase-5 (PDE-
5) inhibitors is sildenafil. It is an agent that was initially developed as an antihypertensive agent. 
However, due to the unexpected side effect of promotion of penile erection in 1998, sildenafil 
citrate (Viagra, Pfizer) has been approved as the first oral drug by the United States Food and 
Drug Administration (FDA) for the treatment of erectile dysfunction. Subsequently, newer 
generation of PDE-5 inhibitors such as vardenafil, tadalafil and udenafil with different 
pharmacokinetics profiles were introduced(37). Sarifakioglu et al. is the first to conduct 
experimental study to evaluate the potential effects of sildenafil of skin flaps survival. He 
demonstrated that oral administration of sildenafil significantly improve skin flap survival in a 
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dose-dependent manner; 20 mg/kg/day for 7 days being the most significant(38). To achieve 
site specific delivery, prolonging exposure of action site and minimizing systemic side effects, 
Ulusoy et al showed that topically applied mixture of fibrin glue and 10 mg of sildenafil on the 
undersurface of flaps can improved skin flap viability(39). Other methods of administration of 
sildenafil via intraperitoneal or local injection with similar dosing regimens has produced 
similar results with improvement of skin flap viability(40-42). With the recent introduction of 
tadafil; PDE-5 inhibitor with longest half life of 17.5 hours, Oh et al has demonstrated that 
subdermal injection of tadafil 10mg/kg daily for 3 days showed significant improvement in 
flap survival(43). Barral et al. in his study using oral tadafil has produced similar trends towards 
improvement in skin flap survival(44), however less significant as compare to Oh et al.   
Phosphodiesterase-3 (PDE3) predominantly dephosphorylate cAMP. Previous clinical 
study with amrinone; a selective PDE-3 inhibitor used clinically in US for the treatment of 
congestive cardiac failure, has shown that it positively influences the microcirculatory blood 
flow on transferred flaps and relieves intraoperative vasospasm(45) Cilostazol, a selective 
inhibitor of phosphodiesterase type III by which it increases cAMP, has recently been approved 
by the UK NICE (National Institute for Health and Care Excellence) and US FDA for use in 
patient with intermittent claudication secondary to peripheral vascular disease. Recent 
experimental trial using oral cilastazol on rats skin flap has shown to improve skin flap survival 
via induction of vasodilation through cAMP dependent pathway or nitric oxide production by 
increase iNOS(46).  
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Figure 3. The NO/cGMP pathway on endothelial smooth muscle with mechanism of action of 
phosphodiesterase inhibitors. Redrawn from Katzung, B. G., Masters, S. B., & Trevor, A. J. 
(2012). Basic and Clinical Pharmacology (12th Edition ed.) SEC II: Cardiovacular and Renal 
pg 196-198l(18). 
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Table 1. List of experimental studies that uses phosphodiesterase class of drugs to improve skin flap survival 
 
 
Author, Year,  Journal  Study design Intervention  Major findings 
Sarifakioglu et al. 
2004(38) 
BJPS Experimental, rat model 
(n=32), Mcfarlane-type 
caudally based skin flap 
Oral solution of sildenafil at 
3,10 or 20 mg/kg/day for 7 days 
 
Sildenafil administered orally have a dose-dependent effect to 
increase flap survival in random skin flaps.  
10 and 20 mg/kg/day showed significant higher survival as 
compare to control (11.7% reduction) 
83.3% (20 mg), 77.4% (10 mg), 71.6% (Control) 
Ulusoy et al. 
2005(39) 
Annals of Plastic 
Surgery 
Experimental, rat model 
(n=50), dorsal random-
pattern skin flap 
Topically applied mixture of 
fibrin glue (0.5 mL) and 
sildenafil at 2.5 mg or 10 mg 
placed under-flap once 
Topically applied sildenafil combined with fibrin glue 
improved skin flap viability in a dose dependent manner (31% 
reduction) 
10 mg sildenafil showed significant decrease in skin necrosis 
compare to 2.5 mg sildenafil 
94.47% (10 mg), 87.9% (2.5mg), 67.3% (Control) 
Ayyildiz et al. 
2005(40) 
Scand J Plast 
Reconstructive 
Surg and Hand 
Surg 
Experimental, rat model 
(n=30), caudally based skin 
flaps 
Orally administered sildenafil 
(1mg/kg/day) compare with 
local injection of sildenafil (0.5 
mg/kg/day) for 7 days 
Locally injected sildenafil is more effective than oral 
sildenafil to improve skin flap viability 
Hart et al.  
2006(41) 
Laryngoscope Experimental, rat model 
(n=109), McFarlane flap on 
dorsal skin 
Intraperitoneal injection of 
sildenafil 9mg/kg/daily for 7 
days 
Intraperitoneally administered sildenafil decrease area of 
necrosis (24% reduction) 
Greater reduction observe at day 1 and day 3 (vasodiltory 
effect) compare to later day 5 and day 7 (angiogenic effect). 
75.1% vs 64.7%(38, 39, 41, 47) 
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Tsai et al. 
2008(42) 
Aesth Plast Surg Experimental, rat model 
(n=123), McFarlane flap on 
dorsal skin 
Intraperitoneal injection of 
sildenafil solution 
(10mg/kg/day) compare with 
VEGF subdermal injection 
(4ug) and compare with 
combination 
Combination of sildenafil and VEGF decreases the extent of 
avascular necrosis and stasis zone in skin flap but no 
difference statistically compare to sildenafil alone. 
Enhancement of flap survival mainly due to sildenafil alone. 
Oh et al. 2008 (43) American 
Dermatological 
Surgery 
Experimental, rats (n=20), 
Mcfarlane caudally based 
axial flap 
Subdermal injection of tadalafil 
10mg/kg postoperatively, day 1 
and day 2 at distal flap 
Increase flap survival following subdermal injection of tadafil 
10mg/kg 
(Reduction of necrosis 15.8%) 
Survival 78.1% vs 63.3% 
Barral et al. 
2011(44) 
Acta Circugica 
Brasileira 
Experimental, rat model 
(n=20), McFarlane skin flap 
on dorsal skin 
Subdermal injection of 
sildenafil (0.5 mg/kg/day) 
immediately post op, and 48 
hours later at nine points 
Subdermal sildenafil is associated with lower skin flap 
viability (Increase necrosis 2.57%) 
Brewer et al. 
2012(47) 
Eplasty Experimental, rats (n=37), 
Mcfarlane random flap 
Oral tadalafil 10mg, 20 
mg/kg/day preoperatively and 
daily for 6 days 
Increased flap survival with 10 mg or 20 mg/kg oral tadalafil 
but statistically not significant (Reduction of 4%) 
81% vs 77% 
Buruspat et al.  
2015(46) 
Annals of surgical 
innovation and 
research 
Experimental, rat model 
(n=30) 
Mcfarlane random dorsal 
flap,  
Oral cilostazol (40 mg/kg/day) 
preoperatively and daily for 7 
days  
(Phosphodiesterase III inhibitor) 
Significant improvement in flap survival at day 3, day 5 and 
day 7 compare to control group (Reduction of necrosis 9.68%) 
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In conclusion, phosphodiesterase inhibitors class of medication has been shown to 
improve skin flap survival in various experimental studies as shown. The experimental design, 
dosing and method of administration were consistent in most of the studies and consistent 
findings were produced. In addition, through this pathway, additional mechanism has been 
postulated to improve skin flap survival that has yet to be explained at this present moment. 
The shortfalls in majority of these studies were the use of oral, intraperitoneal of subdermal 
injection as administration method which complicate the ease of administration and potentially 
causes systemic side effects. Hence, topical application offers great potential to ease the 
administration on skin flap, to deliver site specific medication targeting at subdermal 
microcirculatory level and thus minimizes systemic side effect. Sildenafil, the oldest drug in 
this class of medication, are generally safe and has been used for years in human subjects for 
other treatment indications. Hence, sildenafil is chosen as active ingredient to be formulated as 
topical agents to improve flap survival. Rabbit is chosen as experimental model due to its close 
homology of rabbit’s skin to human’s integument as compared to rat model and axially based 
flap has more predictable vascularity and angiosome as compared to random flap. The aim of 
this study is to determine the effect of our gel formulated sildenafil application on inferior 
epigastric abdominal skin flap in rabbit model. We postulated that single application of 
sildenafil-formulated gel will improve blood perfusion of skin flap and reduce skin flap 
necrosis.  
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2.1.1 Introduction 
Flap survival remains the most important outcome measure in any flap reconstructive surgery. 
Flap failure can result in total failure or partial failure secondary to inadequate flap perfusion. 
Failure of flap surgery will result in devastating complication to the patient with higher cost, 
prolong hospitalization and possibly more surgery with additional donor site morbidity. Recent 
refinements in microsurgery has ensured high success rate in free tissue transfer approaching 95 
percent(1-3). However, most common clinical problem in flap surgery is partial necrosis rather 
than total flap failure. Satisfactory perfusion of bulky perforator flaps, random or pedicled flaps 
and functional muscle flaps remains a challenging problem for reconstructive surgeons(4). 
 Understanding the anatomic, hemodynamic and metabolic changes during flap transfer in 
a free or pedicled flap will determine the flap viability. A flap is a unit of tissue that maintains its 
own blood supply while being transferred from their original bed of body (donor site) to an 
adjacent or distant area (recipient site)(5). The intrinsic blood supply of a flap is the most critical 
determinant of successful transfer. Angiosome concept was first described by Taylor and Palmer 
in 1987 and has since become well accepted in the field of plastic and reconstructive surgery(6). 
It allows the conceptualization of the vascular supply to all tissues of the human body. An 
angiosome is a composite block of tissue supplied by a main source vessel. This concept indicates 
that the three-dimensional block of tissue is supplied by a major source of artery and 
acoompanying veins. The adjacent angiosomes are linked either by reduced calibre choke 
anastomotic vessels or vessels without reduction in calibre; the true (simple) anastomoses on the 
arterial side. The choke vessels can potentially dilate to the calibre of a true anastomosis after 
surgical delay or pharmacological manipulation. Improper flap design exceeding the intrinsic 
blood supply for the flap often leads to partial flap necrosis. Hence, this angiosome concept is 
applicable in any flap reconstructive surgery.   
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 Distal flap ischemia usually results from the inability to maintain critical capillary pressure 
to perfuse the most distal part of the flap where total flap failure is usually caused by global 
insufficiency of blood supply secondary to mechanical obstruction to the pedicle, or no reflow 
phenomenon(4). Distal necrosis is attributed to the development of low flow state at the level of 
microcirculation caused by improper flap design, vasospasm, ischemic reperfusion injury, and 
systemic factors affecting microcirculation or physical compression of the flap. An acutely raised 
flap is both viable and ischemic. In normal hemodynamics, blood flow in the flap tip decreases 
20% below normal levels within first 6 to 12 hours(1, 7). During the first 12- 18 hours, leukocyte-
mediated endothelial damage, release of sympathetic vasoconstrictors and combination of 
decreased perfusion pressure flow dramatically decreases in the distal flap regions(8). Nutritive 
supply at the distal or marginal skin flap edge is compromise and this will lead to partial flap 
necrosis especially in the random part of the flap. When tip regions are exposed to severe ischemia 
for 6- 12 hours with no reflow-phenomenon sets in, tissue necrosis results in cellular changes in 
microcirculation level. By understanding the fundamental pathophysiology of flap 
microcirculation, various study has been conducted to further explained and proposed various 
pathogenic pathway leading to flap failure. As a result, various methods have been proposed to 
augment the flap survival based on these pathways.   
 Various surgical and non-surgical methods have been proposed to augment the survival of 
flaps; surgical delayed remains the most well understood technique to improve flap survival. 
However, this procedure has its disadvantage of only being available before the main surgery and 
requires a two-staged procedure with significant time delayed. The use of pharmacological agents 
to improve flap survival was and is still largely studied experimentally(9-11). Several agents used 
has shown good and promising results experimentally, however these drugs required high dosage, 
impractical method of administration and may cause significant adverse effects; hence it was 
difficult to be translated into clinical use. Hence, there is still a continue search for an effective 
